bioRxiv preprint doi: https://doi.org/10.1101/2020.12.11.420232; this version posted June 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title Pioneer activity of an oncogenic fusion transcription factor at inaccessible chromatin Authors Benjamin Sunkel1,6, Meng Wang1,6, Stephanie LaHaye2,6, Benjamin J. Kelly2, James R. Fitch2, FreDeric G. Barr3, Peter White2,4, Benjamin Z. Stanton1,4,5,7,* Author Affiliations 1 Nationwide Children’s Hospital, Center for Childhood Cancer and Blood Diseases, Columbus, OH 43205, USA 2 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USA 3 Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA 4 Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43210, USA 5 Department of Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH 43210, USA 6These authors contributed eQually 7Lead contact *Correspondence:
[email protected] (B.Z.S.) Summary Recent characterizations of pioneer transcription factors have leD to new insights into their structures anD patterns of chromatin recognition that are instructive for understanding their role in cell fate commitment and transformation. Intersecting with these basic science concepts, the iDentification of pioneer factors (PFs) fuseD together as Driver translocations in chilDhooD cancers raises questions of whether these fusions retain the funDamental ability to invade repressed chromatin, consistent with their monomeric PF constituents.